Abstract
Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy. All published studies reporting monthly OS rates of mCRPC patients receiving third-line NA after having previously received docetaxel and another NA have been analyzed. The treatments were merged into three groups: one NHA followed by another, one NHA followed by CABA, and CABA followed by one NHA. The cumulative monthly OS rates in each group were determined using a weighted-average approach. Thirteen retrospective studies including 1016 patients who received NHA/NHA (469), NHA/CABA (318) or CABA/NHA (229) were evaluated. The 12-month OS rates were 28.5%, 61.3%, and 76.4%, respectively. There were no statistically significant differences in terms of known prognostic factors. Although the retrospective nature of the studies and potential selection biases, our data seem to conf...Continue Reading
References
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas J Vogelzang
Jul 22, 2009·PLoS Medicine·Alessandro LiberatiDavid Moher
Jul 23, 2009·Annals of Internal Medicine·Alessandro LiberatiDavid Moher
Oct 5, 2010·Lancet·Johann Sebastian de BonoUNKNOWN TROPIC Investigators
Sep 1, 2011·European Urology·Jerome P Richie
Nov 15, 2011·The Journal of Urology·Patrick C Walsh
Mar 6, 2012·Urology·Orazio CaffoEnzo Galligioni
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Apr 12, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y LoriotC Massard
Apr 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K L NoonanK N Chi
Oct 1, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D BianchiniJ S de Bono
Nov 10, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R J van SoestW M van Weerden
Nov 22, 2013·Scandinavian Journal of Urology·Frederik Birkebaek ThomsenPeter Iversen
Jan 3, 2014·Cancer·Sushil BadrisingAndries M Bergman
Jan 15, 2014·European Urology·Carmel J PezaroGerhardt Attard
Jan 21, 2014·Advances in Therapy·Sebastian Christoph SchmidMargitta Retz
Jan 28, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David ThomsonOmi Parikh
Feb 22, 2014·Cancer Research·Maria Thadani-MuleroParaskevi Giannakakou
May 27, 2014·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Ryan W DobbsDaniel J Canter
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Jul 24, 2014·The Prostate·Daniel L SuzmanEmmanuel S Antonarakis
Jul 30, 2014·Clinical Genitourinary Cancer·Avishay SellaDaniel Keizman
Oct 30, 2014·The New England Journal of Medicine·Tomasz M Beer, Bertrand Tombal
Feb 25, 2015·Clinical Genitourinary Cancer·Tian ZhangAndrew J Armstrong
Mar 7, 2015·Clinical Genitourinary Cancer·Guru SonpavdeIan Schnadig
Citations
Feb 10, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J CassinelloL Antón Aparicio
Jan 29, 2016·Der Urologe. Ausg. A·C ThomasA Heidenreich
Sep 1, 2015·European Urology·Orazio CaffoAntonello Veccia
Apr 30, 2017·Expert Opinion on Pharmacotherapy·Maria PicciottoVincenzo Adamo
Dec 22, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Kazumasa KomuraPhilip W Kantoff
Jan 5, 2018·Prostate Cancer and Prostatic Diseases·Chris ParkerNeal Shore
May 2, 2019·Der Urologe. Ausg. A·C WülfingM Schostak
Jun 7, 2019·Drugs & Aging·Myrto BoukovalaEleni Efstathiou
Dec 22, 2019·Cancers·Doo Yong ChungKang Su Cho
Oct 1, 2019·The New England Journal of Medicine·Ronald de WitUNKNOWN CARD Investigators
Aug 19, 2017·Medical Oncology·Yukari BandoMasato Fujisawa
Nov 30, 2019·Der Urologe. Ausg. A·P AlbersM De Santis
May 29, 2018·Der Urologe. Ausg. A·M SchostakA Heidenreich
Aug 20, 2019·Future Oncology·Orazio CaffoCarlo Messina
Oct 27, 2017·Der Urologe. Ausg. A·J E GschwendC Thomas
Dec 17, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Finn Edler von EybenTimo Joensuu
Oct 6, 2020·Therapeutic Advances in Medical Oncology·Javier PuenteAránzazu González-Del-Alba
Nov 28, 2020·Expert Review of Anticancer Therapy·Orazio CaffoCarlo Messina
Dec 22, 2020·Der Urologe. Ausg. A·Christian WülfingMartin Schostak
Aug 28, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Özgecan DülgarMahmut Gümüş
Jan 30, 2021·Future Oncology·Orazio CaffoGiuseppe De Vincentis
Jan 9, 2021·BMC Cancer·Peng-Fei ZhangQiu Li
Mar 7, 2021·Diagnostics·Ciara S McNevinStephen P Finn
Aug 24, 2019·Clinical Genitourinary Cancer·Hans M WestgeestWinald R Gerritsen
May 21, 2021·Prostate Cancer and Prostatic Diseases·Matteo BaucknehtDomenico Albano
Jul 21, 2021·Advances in Therapy·Neal D ShoreSameer R Ghate
May 5, 2020·European Urology Focus·Jessica C L NotohardjoAlfons J M van den Eertwegh